

IVMB0511

Product Information

Product SKU: IVMB0511	Clone: ABT-874	Target: IL-12/IL-23 p40
Size: 100 µg		Isotype: Human IgG1λ

Additional Information

Reactivity: Human	Host Species: Human
Antibody Type: Biosimilar Recombinant Human Monoclonal Antibody	Expression Host: HEK-293 Cells

Immunogen Information

Background: Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Product Concentration: 0.2 mg/ml

Applications: FA

Synonyms: IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23

Antigen Distribution: IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.

- Immunogen:** This antibody was produced by phage display technology.
- Formulation:** This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
- Specificity:** This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
- Pathogen Testing:** -
- Storage & Handling:** This DyLight 488 conjugate is stable when stored at 2-8°C. Do not freeze.